 NEW YORK and LONDON, Aug. 17, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc Nasdaq: TLSA LSE: TILS Tiziana or the Company, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology titled Nasal Administration of Anti-CD3 Monoclonal Antibody Foralumab Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study 1. The study was completed in collaboration with scientific teams at the Harvard Medical School Boston, USA and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil. The aim of the study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate COVID-19 patients who were outpatients at the Santa Casa de Misericordia de Santos Hospital in Brazil. Thirty-nine patients were randomized into three cohorts: no Foralumab treatment control, nasal Foralumab 100 ug Dexamethasone 6 mg orally on days 1-3, and nasal Foralumab 100 ug alone administered for 10 consecutive days. All arms were allowed to continue standard of care medications. To view the online publication, please click here: 